Home »
Academic Articles »
C »
Cracking rare disorders: a new minimally invasive RNA-seq protocol
Cracking rare disorders: a new minimally invasive RNA-seq protocol
Laurenz De Cock
(Department of Biomolecular Medicine, Ghent University)
Erika D’haenens
(Center for Medical Genetics Ghent, Ghent University Hospital)
Lies Vantomme
(Department of Biomolecular Medicine, Ghent University)
Lynn Backers
(Department of Biomolecular Medicine, Ghent University)
Aude Beyens
(Department of Biomolecular Medicine, Ghent University)
Kathleen BM Claes
(Department of Biomolecular Medicine, Ghent University)
Griet De Clercq
(Department of Biomolecular Medicine, Ghent University)
Robin de Putter
(Center for Medical Genetics Ghent, Ghent University Hospital)
Candy Kumps
(Center for Medical Genetics Ghent, Ghent University Hospital)
Nika Schuermans
(Center for Medical Genetics Ghent, Ghent University Hospital)
Jo Sourbron
(Center for Medical Genetics Ghent, Ghent University Hospital)
Hannes Syryn
(Department of Biomolecular Medicine, Ghent University)
Simon Tavernier
(Center for Medical Genetics Ghent, Ghent University Hospital)
Eva Vanbelleghem
(Department of Biomolecular Medicine, Ghent University)
Olivier Vanakker
(Department of Biomolecular Medicine, Ghent University)
Bart Vandekerckhove
(Cancer Research Institute Ghent (CRIG))
Tim Van Damme
(Center for Medical Genetics Ghent, Ghent University Hospital)
Bert Callewaert
(Department of Biomolecular Medicine, Ghent University)
Annelies Dheedene
(Department of Biomolecular Medicine, Ghent University)
Sarah Vergult
(Department of Biomolecular Medicine, Ghent University)
Björn Menten
(Department of Biomolecular Medicine, Ghent University)
Abstract RNA sequencing (RNA-seq) has become key to complementing exome and genome sequencing for variant interpretation. We present a minimally invasive RNA-seq protocol using short-term cultured peripheral blood mononuclear cells (PBMCs) with and without cycloheximide treatment, enabling detection of transcripts subject to nonsense-mediated decay. While broadly applicable, this protocol is particularly suited for neurodevelopmental disorders, as up to 80% of the genes in our intellectual disability and epilepsy gene panel are expressed in PBMCs. Applied to 46 affected individuals and 15 parents, RNA-seq revealed splicing defects in six of nine individuals with splice variants, allowing reclassification of seven variants. Targeted cDNA analysis confirmed aberrant splicing in four individuals but missed intron retention in two. Global analyses (FRASER, OUTRIDER, and monoallelic expression) supported findings but did not yield new diagnoses. We propose a flowchart integrating RNA-seq into diagnostic workflows. Overall, our protocol is easily implementable, captures complex splicing events, and enhances variant classification.